{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T12:18:35Z","timestamp":1788783515213,"version":"build-2803163510"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T00:00:00Z","timestamp":1704412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T00:00:00Z","timestamp":1704412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100020540","name":"Coherus Biosciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020540","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s12325-023-02735-3","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T07:02:07Z","timestamp":1704438127000},"page":"991-1009","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Randomized, Open-Label Study Conducted to Evaluate the Bioequivalence of Pegfilgrastim-cbqv On-Body Injector Versus Prefilled Syringe in Healthy Male Participants"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7460-6781","authenticated-orcid":false,"given":"Hong","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Civoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanna","family":"Tatarewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Vandenkoornhuyse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Finck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,5]]},"reference":[{"issue":"suppl 5","key":"2735_CR1","doi-asserted-by":"publisher","first-page":"v111","DOI":"10.1093\/annonc\/mdw325","volume":"27","author":"J Klastersky","year":"2016","unstructured":"Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol. 2016;27(suppl 5):v111\u20138.","journal-title":"Ann Oncol"},{"issue":"4","key":"2735_CR2","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1093\/cid\/cir073","volume":"52","author":"AG Freifeld","year":"2011","unstructured":"Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):e56-93.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"2735_CR3","doi-asserted-by":"publisher","first-page":"e552","DOI":"10.1200\/JOP.2016.019588","volume":"13","author":"E Tai","year":"2017","unstructured":"Tai E, Guy GP, Dunbar A, Richardson LC. Cost of cancer-related neutropenia or fever hospitalizations, United States, 2012. J Oncol Pract. 2017;13(6):e552\u201361.","journal-title":"J Oncol Pract"},{"issue":"21","key":"2735_CR4","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","volume":"25","author":"NM Kuderer","year":"2007","unstructured":"Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25(21):3158\u201367.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2735_CR5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.6004\/jnccn.2009.0009","volume":"7","author":"GH Lyman","year":"2009","unstructured":"Lyman GH. Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Canc Netw. 2009;7(1):99\u2013108.","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"2735_CR6","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.clbc.2018.02.003","volume":"18","author":"N Denduluri","year":"2018","unstructured":"Denduluri N, Lyman GH, Wang Y, et al. Chemotherapy dose intensity and overall survival among patients with advanced breast or ovarian cancer. Clin Breast Cancer. 2018;18(5):380\u20136.","journal-title":"Clin Breast Cancer"},{"issue":"11","key":"2735_CR7","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.6004\/jnccn.2015.0166","volume":"13","author":"N Denduluri","year":"2015","unstructured":"Denduluri N, Patt DA, Wang Y, et al. Dose delays, dose reductions, and relative dose intensity in patients with cancer who received adjuvant or neoadjuvant chemotherapy in community oncology practices. J Natl Compr Canc Netw. 2015;13(11):1383\u201393.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"2735_CR8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JOP.2014.001492","volume":"11","author":"D Weycker","year":"2015","unstructured":"Weycker D, Li X, Edelsberg J, et al. Risk and consequences of chemotherapy-induced febrile neutropenia in patients with metastatic solid tumors. J Oncol Pract. 2015;11(1):47\u201354.","journal-title":"J Oncol Pract"},{"issue":"1","key":"2735_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47(1):8\u2013322.","journal-title":"Eur J Cancer"},{"key":"2735_CR10","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1186\/1471-2407-11-404","volume":"11","author":"KL Cooper","year":"2011","unstructured":"Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer. 2011;11:404.","journal-title":"BMC Cancer"},{"key":"2735_CR11","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Hematopoetic growth factors. Version 2.2023. \u00a9 National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed 24 April 2023. To view the most recent and complete version of the guideline go to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. NCCN, National Comprehensive Cancer Network\u00ae (NCCN)"},{"key":"2735_CR12","unstructured":"Udenyca (pegfilgrastim-cbqv) injection, for subcutaneous use. Prescribing information. Coherus Biosciences Inc.; 2023."},{"key":"2735_CR13","unstructured":"Neulasta (pegfilgrastim) injection single-dose prefilled syringe. Prescribing information. Amgen, Inc.; 2021."},{"issue":"6","key":"2735_CR14","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1007\/s00280-015-2731-x","volume":"75","author":"BB Yang","year":"2015","unstructured":"Yang BB, Morrow PK, Wu X, Moxness M, Padhi D. Comparison of pharmacokinetics and safety of pegfilgrastim administered by two delivery methods: on-body injector and manual injection with a prefilled syringe. Cancer Chemother Pharmacol. 2015;75(6):1199\u2013206.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"2735_CR15","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40259-015-0127-4","volume":"29","author":"T Arvedson","year":"2015","unstructured":"Arvedson T, O\u2019Kelly J, Yang BB. Design rationale and development approach for pegfilgrastim as a long-acting granulocyte colony-stimulating factor. BioDrugs. 2015;29(3):185\u201398.","journal-title":"BioDrugs"},{"issue":"2","key":"2735_CR16","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s40487-022-00207-2","volume":"10","author":"SZ Humphreys","year":"2022","unstructured":"Humphreys SZ, Geller RB, Walden P. Pegfilgrastim biosimilars in US supportive oncology: a narrative review of administration options and economic considerations to maximize patient benefit. Oncol Ther. 2022;10(2):351\u201361.","journal-title":"Oncol Ther"},{"issue":"4","key":"2735_CR17","first-page":"3","volume":"7","author":"AW Mulcahy","year":"2018","unstructured":"Mulcahy AW, Hlavka JP, Case SR. Biosimilar cost savings in the United States: initial experience and future potential. Rand Health Q. 2018;7(4):3.","journal-title":"Rand Health Q"},{"issue":"10","key":"2735_CR18","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.1007\/s12325-020-01459-y","volume":"37","author":"B Finck","year":"2020","unstructured":"Finck B, Tang H, Civoli F, Hodge J, O\u2019Kelly H, Vexler V. Pharmacokinetic and pharmacodynamic equivalence of pegfilgrastim-cbqv and pegfilgrastim in healthy subjects. Adv Ther. 2020;37(10):4291\u2013307.","journal-title":"Adv Ther"},{"issue":"3","key":"2735_CR19","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1007\/s12325-021-02024-x","volume":"39","author":"F Civoli","year":"2022","unstructured":"Civoli F, Finck B, Tang H, Hodge J, O\u2019Kelly H, Vexler V. Biosimilar pegfilgrastim-cbqv demonstrated similar immunogenicity to pegfilgrastim in healthy subjects across three randomized clinical studies. Adv Ther. 2022;39(3):1230\u201346.","journal-title":"Adv Ther"},{"issue":"1","key":"2735_CR20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1208\/s12248-019-0386-y","volume":"22","author":"F Civoli","year":"2019","unstructured":"Civoli F, Kasinath A, Cai XY, et al. Recommendations for the development and validation of immunogenicity assays in support of biosimilar programs. AAPS J. 2019;22(1):7.","journal-title":"AAPS J"},{"key":"2735_CR21","unstructured":"US Food and Drug Administration. Assessing the irritation and sensitization potential of transdermal and topical delivery systems for ANDAs. Draft guidance for industry. 2023. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/assessing-irritation-and-sensitization-potential-transdermal-and-topical-delivery-systems-andas. Accessed May 23, 2023."},{"issue":"2","key":"2735_CR22","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/S0897-1897(98)80229-2","volume":"11","author":"DJ Stuppy","year":"1998","unstructured":"Stuppy DJ. The faces pain scale: reliability and validity with mature adults. Appl Nurs Res. 1998;11(2):84\u20139.","journal-title":"Appl Nurs Res"},{"issue":"5","key":"2735_CR23","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2165\/11586040-000000000-00000","volume":"50","author":"BB Yang","year":"2011","unstructured":"Yang BB, Kido A. Pharmacokinetics and pharmacodynamics of pegfilgrastim. Clin Pharmacokinet. 2011;50(5):295\u2013306.","journal-title":"Clin Pharmacokinet"},{"issue":"15_suppl","key":"2735_CR24","doi-asserted-by":"publisher","first-page":"e18273","DOI":"10.1200\/JCO.2017.35.15_suppl.e18273","volume":"35","author":"P Stuessy","year":"2017","unstructured":"Stuessy P, Sanchez FA, Schober M. Retrospective review of pegfilgrastim on-body injector delivery rates in a large health system. J Clin Oncol. 2017;35(15_suppl):e18273.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2735_CR25","first-page":"119","volume":"8","author":"C Townley","year":"2018","unstructured":"Townley C, Porter C, McMullen N. Comparing grade 4 neutropenia associated with pegfilgrastim administered via the Onpro device versus manual injection with a prefilled syringe. JHOP. 2018;8(3):119\u201325.","journal-title":"JHOP"},{"key":"2735_CR26","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2147\/PPA.S50583","volume":"8","author":"F Schwarzenbach","year":"2014","unstructured":"Schwarzenbach F, Dao Trong M, Grange L, et al. Results of a human factors experiment of the usability and patient acceptance of a new autoinjector in patients with rheumatoid arthritis. Patient Pref Adher. 2014;8:199\u2013209.","journal-title":"Patient Pref Adher"},{"key":"2735_CR27","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.2147\/PPA.S154181","volume":"12","author":"S Vermeire","year":"2018","unstructured":"Vermeire S, D\u2019Heygere F, Nakad A, et al. Preference for a prefilled syringe or an auto-injection device for delivering golimumab in patients with moderate-to-severe ulcerative colitis: a randomized crossover study. Patient Prefer Adher. 2018;12:1193\u2013202.","journal-title":"Patient Prefer Adher"},{"issue":"suppl 4","key":"2735_CR28","doi-asserted-by":"publisher","first-page":"S1071","DOI":"10.1016\/j.annonc.2020.08.1531","volume":"31","author":"M Metz","year":"2020","unstructured":"Metz M, Semsek D, Rogmans G, et al. Patient, nurse and physician preferences: final results of the CONVENIENCE study evaluating pegfilgrastim prophylaxis via pre-filled syringe or On-body injector (OBI) in cancer patients. Ann Oncol. 2020;31(suppl 4):S1071.","journal-title":"Ann Oncol"},{"issue":"10","key":"2735_CR29","doi-asserted-by":"publisher","first-page":"7913","DOI":"10.1007\/s00520-022-07226-9","volume":"30","author":"RM Rifkin","year":"2022","unstructured":"Rifkin RM, Crawford J, Mahtani RL, et al. A prospective study to evaluate febrile neutropenia incidence in patients receiving pegfilgrastim on-body injector vs other choices. Support Care Cancer. 2022;30(10):7913\u201322.","journal-title":"Support Care Cancer"},{"key":"2735_CR30","unstructured":"US Department for Health and Human Services. Guidance for industry. Clinical pharmacology data to support a demonstration of biosimilarity to a reference product. Updated May 5, 2020. Silverspring; 2016. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/clinical-pharmacology-data-support-demonstration-biosimilarity-reference-product. Accessed August 10, 2023."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02735-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02735-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02735-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T18:13:39Z","timestamp":1708452819000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02735-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,5]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["2735"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02735-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,5]]},"assertion":[{"value":"15 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hong Tang, Suzanna Tatarewicz, Nathalie Vandenkoornhuyse, and Barbara Finck are employees of and own stock in Coherus BioSciences (Redwood City, CA). Francesca Civoli is a former employee and owns stock in Coherus BioSciences (Redwood City, CA); she is currently affiliated with Francesca Civoli Consulting LLC.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The protocol and informed consent form were reviewed and approved by the Advarra institutional review board (IRB registration number IRB0000097). The study was conducted in accordance with all applicable laws and regulations and complied with the International Conference for Harmonisation E6 Guideline on Good Clinical Practice. All procedures were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}